Thermo Fisher Scientific (NYSE:TMO – Get Free Report) released its earnings results on Wednesday. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28, FiscalAI reports. The company had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. During the same period last year, the business earned $5.79 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 9.1% on a year-over-year basis.
Here are the key takeaways from Thermo Fisher Scientific’s conference call:
- Thermo Fisher raised its 2026 outlook, increasing revenue guidance to $47.7 billion–$48.2 billion, organic growth guidance to 4%, adjusted EPS guidance to $25.13–$25.43, and free cash flow guidance to $7.0 billion–$7.5 billion.
- Third-quarter performance exceeded expectations, with revenue up 9% to $12.14 billion, organic growth of 6%, adjusted EPS up 15% to $6.68, and adjusted operating margin expanding 120 basis points to 24.5%. Growth was led by Pharma Services, clinical research, electron microscopy, and improving biotech demand.
- Management reported continued strengthening in pharma and biotech customer activity, including low-to-mid/high-single-digit growth across key areas, improving biotech funding and confidence, and strong demand for clinical research, bioproduction, and semiconductor-related electron microscopy.
- The quarter benefited from approximately $60 million of net tariff-refund recovery, contributing $0.15 to adjusted EPS, although the company reinvested part of the proceeds in AI deployment, Pharma Services capacity, and employee investments. The refund benefit is largely one-time, while fourth-quarter organic growth guidance remains at 4% after some Pharma Services activity shifted into the third quarter.
- Thermo Fisher highlighted expanding AI capabilities across instruments and services, including AI-enabled cryo-electron microscopy workflows and a clinical research assistant, while the Clario acquisition and bioproduction investments are reportedly generating strong customer adoption and potential revenue synergies.
Thermo Fisher Scientific Stock Up 1.0%
NYSE:TMO opened at $693.98 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company’s fifty day moving average price is $642.42 and its 200-day moving average price is $552.67. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $705.79. The firm has a market capitalization of $256.60 billion, a P/E ratio of 37.33, a PEG ratio of 2.87 and a beta of 0.87.
More Thermo Fisher Scientific News
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Q3 results exceeded expectations. Thermo Fisher reported adjusted EPS of $6.68, above the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, surpassing estimates of approximately $11.95 billion. Adjusted EPS increased 15%, supported by stronger operating performance. Thermo Fisher Scientific Reports Third Quarter 2026 Results
- Positive Sentiment: Organic growth and margins improved. Organic revenue growth reached 6%, with particularly solid demand in clinical research, bioproduction and electron microscopy. Operating margin expanded to 24.5%, aided by portfolio actions, acquisitions and productivity improvements. Thermo Fisher: You Don’t Need A Microscope To See The Growth Anymore
- Positive Sentiment: Management raised its outlook. Thermo Fisher lifted its full-year 2026 organic revenue-growth forecast to 4% and highlighted continued customer activity and confidence in sustained, multi-year expansion. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
- Neutral Sentiment: Early market reaction was volatile. Shares initially declined in premarket trading despite the earnings beat, suggesting that elevated expectations or profit-taking temporarily offset the favorable results before the stock reversed higher. TMO Q3 Earnings and Revenues Beat Estimates
- Negative Sentiment: Unusual put-option activity signals near-term caution. Investors purchased 4,906 put options, about 52% above average daily volume, indicating some traders are hedging against volatility or a pullback following the earnings release.
Insider Activity at Thermo Fisher Scientific
In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on TMO shares. Guggenheim initiated coverage on Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a “buy” rating for the company. BMO Capital Markets downgraded Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. CLSA began coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $664.33.
Read Our Latest Research Report on TMO
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- AI Spending Is Surging—But Which Stocks Still Win if It Slows Down?
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
